Applied Therapeutics Stock Price To Sales
| APLT Stock | USD 8.57 1.64 16.06% |
Applied Therapeutics fundamentals help investors to digest information that contributes to Applied Therapeutics' financial success or failures. It also enables traders to predict the movement of Applied Stock. The fundamental analysis module provides a way to measure Applied Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Applied Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 25.42 | 22.59 |
Applied | Price To Sales |
Applied Therapeutics Company Price To Sales Analysis
Applied Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Applied Therapeutics Price To Sales | 54.68 X |
Most of Applied Therapeutics' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Applied Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Applied Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Applied Therapeutics is extremely important. It helps to project a fair market value of Applied Stock properly, considering its historical fundamentals such as Price To Sales. Since Applied Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Applied Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Applied Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Applied Therapeutics has a Price To Sales of 54 times. This is 155.5% higher than that of the Biotechnology sector and 44.44% lower than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.
Applied Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Applied Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Applied Therapeutics could also be used in its relative valuation, which is a method of valuing Applied Therapeutics by comparing valuation metrics of similar companies.Applied Therapeutics is currently under evaluation in price to sales category among its peers.
Applied Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Applied Therapeutics from analyzing Applied Therapeutics' financial statements. These drivers represent accounts that assess Applied Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Applied Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 350.0M | 483.5M | 229.1M | 28.7M | 282.2M | 176.7M | |
| Enterprise Value | 333.2M | 427.8M | 176.5M | 13.0M | 233.1M | 152.4M |
Applied Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Applied Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Applied Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Applied Fundamentals
| Return On Equity | -4.73 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (243.80) % | ||||
| Current Valuation | 1.09 B | ||||
| Shares Outstanding | 116.36 M | ||||
| Shares Owned By Insiders | 5.23 % | ||||
| Shares Owned By Institutions | 94.77 % | ||||
| Number Of Shares Shorted | 12.14 M | ||||
| Price To Earning | (7.46) X | ||||
| Price To Book | 201.63 X | ||||
| Price To Sales | 54.68 X | ||||
| Revenue | 9.99 M | ||||
| EBITDA | (64.53 M) | ||||
| Net Income | (119.76 M) | ||||
| Cash And Equivalents | 67.72 M | ||||
| Cash Per Share | 1.41 X | ||||
| Total Debt | 777 K | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 1.49 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (55.17 M) | ||||
| Short Ratio | 7.70 X | ||||
| Earnings Per Share | (1.42) X | ||||
| Target Price | 14.67 | ||||
| Number Of Employees | 37 | ||||
| Beta | 2.02 | ||||
| Market Capitalization | 1.19 B | ||||
| Total Asset | 54.83 M | ||||
| Retained Earnings | (468.59 M) | ||||
| Working Capital | (16.8 M) | ||||
| Current Asset | 37.74 M | ||||
| Current Liabilities | 11.19 M | ||||
| Net Asset | 54.83 M |
About Applied Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Applied Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Applied Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Applied Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Applied Stock Analysis
When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.